Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters











Publication year range
1.
Eye Contact Lens ; 44 Suppl 2: S187-S191, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29369234

ABSTRACT

OBJECTIVES: The purpose of this study was to determine whether a commercial formulation of hypochlorous acid hygiene solution (0.01%), Avenova, can destroy existing biofilms formed by ocular clinical bacterial isolates, including blepharitis isolates of Staphylococcus aureus and coagulase-negative staphylococci, and a keratitis isolate of Pseudomonas aeruginosa. METHODS: Biofilms grown in bacterial growth media on disposable contact lens cases were challenged with hypochlorous acid hygiene solution. At various time points, surviving bacteria were quantified by serial dilution and colony counts. Staphylococcus aureus biofilms formed on glass were challenged using a hypochlorous acid hygiene solution and imaged using vital staining and confocal laser scanning microscopy. RESULTS: Bactericidal activity (≥3 Log10; 99.9%) was observed for all tested bacterial species after a 30-min exposure. Staphylococcus aureus biofilms had a bactericidal level of killing by 10 min (P<0.01), Staphylococcus capitis by 5 min (P<0.001), Staphylococcus epidermidis by 30 min (P<0.001), and P. aeruginosa by 10 min (P<0.01). Confocal microscopy and crystal violet staining analysis of bacterial biofilms treated with hypochlorous acid solution both demonstrated that biofilm bacteria were readily killed, but biofilm structure was largely maintained. CONCLUSIONS: Hypochlorous acid (0.01%) hygiene solution was able to achieve bactericidal levels of killing of bacteria in biofilms but did not disrupt biofilm structures. Susceptibility of tested staphylococcal blepharitis isolates varied by species, with S. capitis being the most susceptible and S. epidermidis being the least susceptible.


Subject(s)
Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Hypochlorous Acid/pharmacology , Oxidants/pharmacology , Pseudomonas aeruginosa/drug effects , Staphylococcus/drug effects , Biofilms/growth & development , Blepharitis/microbiology , Contact Lenses/microbiology , Humans , Keratitis/microbiology , Staphylococcus aureus/drug effects , Staphylococcus capitis/drug effects , Staphylococcus epidermidis/drug effects
2.
Arch Soc Esp Oftalmol ; 90(3): 112-8, 2015 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-25542616

ABSTRACT

OBJECTIVE: To compare the efficacy of 3 treatment options in patients with chronic blepharitis. METHODOLOGY: An experimental, randomized, controlled study was conducted on 45 patients (female 67%; Mean age: 40.5 years) diagnosed with chronic blepharitis, in order to compare the effectiveness of three treatment options. Group 1: eyelid hygiene with neutral shampoo three times/day; group 2: neutral shampoo eyelid hygiene plus topical metronidazole gel 0.75% twice/day; group 3: neutral eyelid hygiene with shampoo plus neomycin 3.5% and polymyxin 10% antibiotic ointment with 0.5% dexamethasone 3 times/day. The symptoms and signs were assessed by assigning scores from 0: no symptoms and/or signs; 1: mild symptoms and/or signs, 2: moderate symptoms and/or signs; and 3: severe symptoms and/or signs. RESULTS: A significant improvement was observed in the signs and symptoms in all 3 treatment groups. While groups 1 and 2 had more improvement in all variables studied (P<.05), Group 3 showed no clinical improvement for itching (P=.16), dry eye (P=.29), eyelashes falling (P=.16), and erythema at the eyelid margin (P=.29). CONCLUSIONS: Shampoo eyelid hygiene neutral and neutral shampoo combined with the use of metronidazole gel reported better hygiene results than neutral shampoo lid with antibiotic ointment and neomycin and polymyxin dexamethasone.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Blepharitis/therapy , Therapeutic Irrigation , Administration, Ophthalmic , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Anti-Bacterial Agents/administration & dosage , Blepharitis/drug therapy , Blepharitis/microbiology , Blepharitis/parasitology , Chronic Disease , Dexamethasone/administration & dosage , Dexamethasone/therapeutic use , Eyelashes , Female , Gels , Hair Preparations , Humans , Male , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Middle Aged , Mite Infestations/drug therapy , Mite Infestations/therapy , Mites , Neomycin/administration & dosage , Neomycin/therapeutic use , Ointments , Pneumococcal Infections/drug therapy , Pneumococcal Infections/therapy , Polymyxins/administration & dosage , Polymyxins/therapeutic use , Severity of Illness Index , Staphylococcal Infections/drug therapy , Staphylococcal Infections/therapy , Treatment Outcome , Young Adult
3.
Adv Ther ; 29(5): 416-26, 2012 May.
Article in English | MEDLINE | ID: mdl-22562783

ABSTRACT

INTRODUCTION: Treatments that offer two medications in a fixed combination have the potential to offer efficacious and safe treatment with advantages such as a regimen that is simpler than administering two separate solutions. This study evaluated the safety and efficacy of fixed-combination versus concomitant moxifloxacin 0.5% and dexamethasone 0.1% ocular solutions for the treatment of bacterial ocular inflammation and infection. METHODS: The clinical study design was a randomized, double-masked, active-controlled, parallel-group trial of 102 subjects with bacterial blepharitis in which two patients also had bacterial conjunctivitis. All subjects received two bottles of study medication: either a fixed combination of moxifloxacin 0.5%/dexamethasone 0.1% ophthalmic solution and placebo eye drops (fixed-dose group), or moxifloxacin 0.5% ophthalmic solution and dexamethasone 0.1% (concomitant group). One drop of each study medication was instilled bilaterally four times per day for 7 days. Clinical resolution, signs, symptoms, and safety were assessed. Microbiological specimens were collected from the eyelid margin and conjunctivae of each eye from each patient at the time of enrollment and at the exit visit. RESULTS: Clinical resolution occurred similarly in both groups (81.6% of eyes, fixed-dose group; 82.3% of eyes, concomitant group). Moreover, the microbiological efficacy of the treatment was also similar for both the fixed-dose group (84%) and the concomitant group (83%). Ocular symptoms and signs improved over time, with no significant differences between groups after 7 days of treatment, except the fixed-dose group had significantly more eyes with clinical resolution in eyelid erythema (100%, n = 98/98, fixed-dose group; 92.7%, n = 89/96, concomitant group; P = 0.0194) and eyelid scaling/crusting (98%, n = 96/98, fixed-dose group; 89.6%; n = 86/96 eyes, concomitant group; P = 0.0337). Both regimens were safe and well tolerated. CONCLUSION: The fixed-dose combination of moxifloxacin, 0.5% and dexamethasone, 0.1% was therapeutically equivalent and as well tolerated as the concomitant dosage.


Subject(s)
Anti-Infective Agents/therapeutic use , Aza Compounds/therapeutic use , Blepharitis/drug therapy , Dexamethasone/therapeutic use , Eye Infections, Bacterial/drug therapy , Glucocorticoids/therapeutic use , Quinolines/therapeutic use , Administration, Ophthalmic , Adult , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/adverse effects , Aza Compounds/administration & dosage , Aza Compounds/adverse effects , Blepharitis/microbiology , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Double-Blind Method , Drug Combinations , Eye Infections, Bacterial/microbiology , Female , Fluoroquinolones , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Male , Middle Aged , Moxifloxacin , Quinolines/administration & dosage , Quinolines/adverse effects
4.
Cornea ; 30(10): 1145-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21849891

ABSTRACT

PURPOSE: To evaluate the effects of oral azithromycin in patients with posterior blepharitis. METHODS: Twenty-six eyes of 13 patients with posterior blepharitis diagnosed by a qualified ophthalmologist were enrolled in this study. Patients were instructed to use oral azithromycin 500 mg per day for 3 days in 3 cycles with 7-day intervals. Subjective clinical outcomes were graded and scored 1 day before and 30 days after the end of the treatment (53 days after initiating the treatment) based on severity scores of: (1) eyelid debris; (2) eyelid telangiectasia; (3) swelling of the eyelid margin; (4) redness of the eyelid margin; and (5) ocular mucus secretion. For the assessment of global efficacy, patients were asked by the investigator to rate the subjective symptoms (eyelid itching, ocular itching, eyelid hyperemia, ocular hyperemia, ocular mucus secretion, photophobia, foreign body sensation, and dry eye sensation) on a scale of 0 (no symptoms) to 5 (severe symptoms). Break-up time, Schirmer I test, corneal fluorescein staining score, and rose bengal staining score were also performed in all patients. RESULTS: All clinical outcomes scoring showed statistically significant improvement after oral azithromycin, except for eyelid swelling. Average subjective symptom grading improved statistically after treatment with oral azithromycin, except for eyelid hyperemia, photophobia, and foreign body sensation. Average tear film break-up time values showed statistically significant improvement after the treatment with oral azithromycin. No statistically significant improvement was observed on average values of Schirmer I test, corneal fluorescein staining score, and rose bengal staining score. CONCLUSIONS: The combination of multiple clinical parameters shown in this study supports the clinical efficacy of pulsed oral azithromycin therapy for the management of posterior blepharitis.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Azithromycin/administration & dosage , Blepharitis/drug therapy , Eye Infections, Bacterial/drug therapy , Meibomian Glands/drug effects , Administration, Oral , Blepharitis/microbiology , Eye Infections, Bacterial/microbiology , Female , Humans , Hyperemia/drug therapy , Hyperemia/physiopathology , Male , Meibomian Glands/microbiology , Middle Aged , Prospective Studies , Pruritus/drug therapy , Pruritus/physiopathology , Pulse Therapy, Drug , Tears/chemistry , Treatment Outcome
5.
Arq. bras. oftalmol ; Arq. bras. oftalmol;72(6): 822-825, Nov.-Dec. 2009. ilus
Article in Portuguese | LILACS | ID: lil-536779

ABSTRACT

O acometimento ocular da paracoccidioidomicose é raro e quando ocorre é geralmente secundário à disseminação hematogênica. Descrição de um caso de paracococcidioidomicose multifocal em homem de 73 anos com história de trauma contuso no olho direito por pedaço de madeira e que teve como primeira manifestação clínica lesão palpebro-conjuntival. Interroga-se possível infecção primária ocular por contiguidade e alerta-se para a manifestação da doença em idade mais avançada.


Ocular involvement of paracoccidioidomycosis is rare and when it occurs it is usually secondary to hematogenic dissemination. A case of multifocal paracoccidioidomycosis in a 73 year-old male after history of blunt trauma in the right eye with a stick of wood that presented as the first clinical sign a lid-conjunctival lesion is described. The possible primary ocular infection spreading by contiguity is argued and the disease manifestation in an advanced age is highlighted.


Subject(s)
Aged , Humans , Male , Blepharitis/complications , Eye Injuries/complications , Paracoccidioidomycosis/microbiology , Wounds, Nonpenetrating/complications , Blepharitis/microbiology
6.
Arq Bras Oftalmol ; 72(6): 822-5, 2009.
Article in Portuguese | MEDLINE | ID: mdl-20098907

ABSTRACT

Ocular involvement of paracoccidioidomycosis is rare and when it occurs it is usually secondary to hematogenic dissemination. A case of multifocal paracoccidioidomycosis in a 73 year-old male after history of blunt trauma in the right eye with a stick of wood that presented as the first clinical sign a lid-conjunctival lesion is described. The possible primary ocular infection spreading by contiguity is argued and the disease manifestation in an advanced age is highlighted.


Subject(s)
Blepharitis/complications , Eye Injuries/complications , Paracoccidioidomycosis/microbiology , Wounds, Nonpenetrating/complications , Aged , Blepharitis/microbiology , Humans , Male
7.
Mycoses ; 48(1): 73-5, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15679671

ABSTRACT

We report a case of tinea on the eyelid in a woman with psoriasis. Due to the history of psoriasis and clinical aspect of the lesion the diagnosis of psoriasis was suggested in the first place; however, laboratory examination revealed Microsporum gypseum. The patient was treated with oral itraconazole resulting in clinical and mycological cure. We emphasize the uncommon location of tinea caused by M. gypseum and the importance of searching for fungal infection on scaly lesions.


Subject(s)
Blepharitis/microbiology , Dermatomycoses/microbiology , Eyelids/microbiology , Microsporum/isolation & purification , Adult , Antifungal Agents/therapeutic use , Blepharitis/drug therapy , Dermatomycoses/drug therapy , Female , Humans , Itraconazole/therapeutic use , Treatment Outcome
8.
Rev. méd. Hosp. Gen. Méx ; 58(4): 151-6, oct.-dic. 1995. tab
Article in Spanish | LILACS | ID: lil-180613

ABSTRACT

Se diseño un estudio doble ciego, prospectivo, longitudinal y experimental comparando la eficacia, tolerancia y toxicidad de la criprofloxacina y la tobramicina tópica al 0.3 por ciento en el tratamiento de las blefaroconjuntivitis y las queratoconjuntivitis. Se incluyeron 40 ojos en cada grupo, encontrando que ambos fármacos son igualmente efectivos para erradicar o reducir los gérmenes causantes de infección en un 95 por ciento. La ciprofloxacina dismuyó el lagrimeo y prurito en forma estadísticamente más importante (p<0.05) que la tombracina además de ser mejor tolerada y no haber provocado efectos tóxicos secundarios


Subject(s)
Humans , Male , Female , Tobramycin/administration & dosage , Tobramycin/pharmacology , Blepharitis/microbiology , Blepharitis/drug therapy , Ciprofloxacin/administration & dosage , Ciprofloxacin/pharmacology , Keratoconjunctivitis, Infectious/microbiology , Keratoconjunctivitis, Infectious/drug therapy , Anti-Bacterial Agents/pharmacology , Ophthalmic Solutions/administration & dosage
9.
Mycopathologia ; 102(2): 87-96, 1988 May.
Article in English | MEDLINE | ID: mdl-3405277

ABSTRACT

We present 6 patients with ocular involvement due to paracoccidioidomycosis. All cases were confirmed by the finding of Paracoccidioides brasiliensis in histopathological or direct mycologic examination of material from the lesion in the eyelid or conjunctiva. In two cases the bulbar conjunctiva was also involved, in another the cornea, and still another patient developed endophthalmitis. The presence of this mutilating disease which may lead to blindness should be suspected when chronic blepharitis or palpebral ulcerated papular lesions are detected in patients from endemic areas of paracoccidioidomycosis. This etiology should also be suspected in patients with anterior and posterior uveitis after discarding the most frequent causes of this condition.


Subject(s)
Eye Diseases/microbiology , Paracoccidioidomycosis/pathology , Adult , Blepharitis/microbiology , Conjunctival Diseases/microbiology , Eye Diseases/pathology , Eyelid Diseases/microbiology , Humans , Male , Middle Aged , Paracoccidioides , Uveitis/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL